All In Biotech

Drug Trial Radar · NCT07389460

Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)

Intravenous rhPro-UK Versus Placebo Before Endovascular Thrombectomy For Stroke Patient With Large Vessel Occlusion In The Extended Time Window: the Randomized, Placebo-controlled, Double-blind Trial (BRIDGE-PUK EXTEND )

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 820 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

820

Planned (sponsor's estimate)

Start

Apr 7, 2026

Primary completion

Dec 31, 2027

Study completion Mar 31, 2028

Sponsor

Lead sponsor
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Tasly Pharmaceutical Group Co., Ltd; Peking Union Medical College Hospital
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled phase III clinical trial aims to evaluate the efficacy and safety of intravenous recombinant human Prourokinase (rhPro-UK) in acute ischemic stroke patients with large vessel occlusion presenting 4.5-24 hours after last known well. The study will address two primary questions: 1) Whether rhPro-UK enhances pre-thrombectomy reperfusion rates and improves 90-day functional outcomes compared to placebo; 2) Whether rhPro-UK increases the risk of symptomatic intracranial hemorrhage and mortality. Participants will be randomized to receive an intravenous bolus of rhPro-UK or matching placebo, with a total dose of 35mg (15mg administered as an intravenous push within 5 minutes, and the remaining 20mg continuously infused intravenously over 30 minutes). Key assessments include repeat neuroimaging (CT/CTA or MRI/MRA) at 24 hours post-treatment to evaluate reperfusion, NIH Stroke Scale score at day 5-7, and modified Rankin Scale score assessment at 90 days. Safety monitoring will focus on hemorrhagic transformation and mortality events throughout the study period.

Conditions

  • Acute Ischemic Stroke

Interventions

  • Intravenous rhPro-UKDrug

    Patients will receive intravenous rhPro-UK

  • Intravenous placeboDrug

    Patients will receive intravenous placebo

  • Endovascular thrombectomyProcedure

    Patients will receive endovascular thrombectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients functionally independent (mRS score 0 to 2) at 90 daysTime frame: 90 days post-randomization

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital Capital Medical University

    Beijing, China · Recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Recruiting

  • The Third Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • Loudi Central Hospital

    Loudi, Hunan, China · Recruiting

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China · Recruiting

  • Qinghai Provincial People's Hospital

    Xining, Qinghai, China · Recruiting

  • First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Recruiting

  • Shanxi Cardiovascular Hospital

    Taiyuan, Shanxi, China · Recruiting

  • The First Affiliated Hospital of Shihezi University

    Shihezi, Xinjiang Uygur Autonomous Region, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.